U.S. Markets closed

Acorda Therapeutics (ACOR) in Focus: Stock Tumbles 9%

Zacks Equity Research

Acorda Therapeutics, Inc. (ACOR) saw a big move last session, as the company’s shares fell by nearly 9% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session.  This reverses the recent trend for DRYS, as the stock is now up 3.8% in the past one-month time frame.

Acorda Therapeutics has seen a mixed track record when it comes to current year estimate revisions over the past few weeks (no increase, no decrease), and the consensus for earnings hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump.

ACOR currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the pharmaceutical sector include ANI Pharmaceuticals, Inc. (ANIP), Gilead Sciences Inc. (GILD) and Illumina Inc. (ILMN). All these stocks hold a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

ACORDA THERAPEUTICS INC (ACOR): Free Stock Analysis Report

Zacks Investment Research